Medivir Discontinues NS5A Inhibitor Program
Share
Follow Us
Medivir Makes Strategic Decision to Focus Proprietary Hepatitis C R&D Efforts Exclusively on Nucleotide-Based Polymerase Inhibitors
STOCKHOLM–(BUSINESS WIRE)–August 15, 2013–
Regulatory News:
Medivir AB (STO:MVIR-B) (OMX: MVIR) today announced that it will focus its proprietary hepatitis C (HCV) research and development efforts exclusively on nucleotide-based polymerase inhibitors.
Medivir had been working on the discovery and development of new HCV nucleotide-based inhibitors and NS5A inhibitors (NS5A replication complex inhibitor) to enable additional potential interferon-free combinations. However, based on an evaluation of the competitive landscape and the expected evolution of therapies for HCV infection, Medivir has decided to focus exclusively on nucleotide-based polymerase inhibitors and to discontinue its NS5A inhibitor program.
Continue reading this entire article:
http://online.wsj.com/article/PR-CO-20130815-903829.html
